{
  "entity_id": "B-002552",
  "folder": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
  "name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
  "type": "Statutory Body",
  "jurisdiction": "Commonwealth",
  "portfolio": "Health, Disability and Ageing",
  "website": "https://www.safetyandquality.gov.au/about-us/committees#primary-care-committee",
  "data_status": "partial",
  "completeness": {
    "has_strategy_brief": false,
    "has_strategy_structured": true,
    "has_vision": false,
    "has_kpi_targets": false,
    "has_kpi_results": false,
    "has_strategy_overview": true,
    "has_legislation_text": true,
    "has_legislation_structured": false,
    "has_global_initiatives_text": false,
    "has_ideas": true,
    "has_artifacts": true,
    "n_ideas": 12,
    "n_legislation": 0,
    "n_artifacts": 3,
    "n_kpi_targets": 0,
    "n_kpi_results": 0,
    "n_outcomes": 0,
    "verified_own_data": true
  },
  "strategy_profile": {
    "status": "needs_review",
    "confidence": "medium",
    "summary": "",
    "official_site_url": "https://www.safetyandquality.gov.au/about-us/committees#primary-care-committee",
    "source_documents": [
      {
        "type": "strategie",
        "title": "MaPSaF",
        "url": "https://www.ajustnhs.com/wp-content/uploads/2012/10/Manchester-Patient-Safety-Framework.pdf",
        "period": "2012",
        "confidence": "medium"
      }
    ],
    "purpose": null,
    "vision": null,
    "strategic_priorities": [],
    "values": [],
    "outcomes": [],
    "performance_measures": [],
    "document_alignment_terms": {
      "must_support": [],
      "watch_terms": [],
      "avoid_claiming_without_evidence": []
    },
    "review_note": "Structured strategy exists but is incomplete."
  },
  "strategy_brief_md": null,
  "strategy_overview_evidence_md": null,
  "internal_strategy_evidence_md": "# Australian Commission on Safety and Quality in Health Care's Primary Care Commit - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T22:20:37.501724+00:00\n**Entity ID**: B-002552\n**Entity type**: Statutory Body\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: https://www.safetyandquality.gov.au/about-us/committees#primary-care-committee\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| other-pdfs | 2 |\n| pages | 25 |\n| strategies | 1 |\n\n## Executive Readout\n\n### Purpose\n\n- [pages 46,47,48]\nrocedures and protocols that define a vision, principles, objectives, practices, roles and\nfunctions, resources, service outcomes and how outcomes will be measured\n■ Ensure that enough resources are allocated to the health service organisation’s risk\nmanagement system\n■ Foster an organisational culture that focuses on quality clinical trial service provision and\ncontinuous improvement in identifying and managing risk\n■ Incorporate systematic audits of safety and quality systems relating to clinical trial service provision\nin the whole-of-organisation audit program\n■ Ensure availability of data and information to support quality assurance and review of clinical trial\nservices across the health service organisation or trial site\n42 | Australian Commission on Safety and Quality in Health Care\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- These shared ways of ■ Clear responsibilities for managing high-\nthinking are then translated into common and quality clinical trial services and appropriate\nrepeated patterns of behaviour: patterns of delegation of the necessary management\nbehaviour that are in turn maintained and authority for this purpose\nreinforced by the rituals, ceremonies and\n■ Reliable processes for ensuring that systems\nrewards of everyday organisational life.24\nfor delivering clinical trials perform well, and\nFactors that have been identified as being clinicians are fully engaged in the design,\nimportant for sustaining cultures that ensure monitoring and development of these\nclinical trials are delivered in a high-quality systems\nmanner and promote safety standards ■ Effective use of data and information to\ninclude:25,26 monitor and report on operational\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [pages 14,15,16,17]\nvement\n■ Translating the vision into clear objectives for ■ Well-designed systems for identifying,\nsafety and quality at all levels of the quantifying, and managing risk\norganisation, and establishing measures to ■ Opportunities for consumer engagement in\nassess progress the design of clinical trial services and\n■ Providing a supportive and positive working processes that supports consumer\nenvironment for the workforce engagement as a part of the health service\norganisation strategic plan.\n■ Ensuring that members of the workforce are\nengaged in their work\n■ Having an organisation that is transparent\nabout performance, open to learning and\ncontinuously improving\n■ Supporting multidisciplinary teams to work\ntogether effectively.\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- The governing body should:\n■ Determine the health service organisation’s risk appetite and tolerance – that is, the amount and\ntype of risk that an organisation is willing to take to meet its strategic objectives for delivery clinical\ntrial services\n■ Ensure that the health service organisation’s risk management system is clearly documented in\npolicies, procedures and protocols that define a vision, principles, objectives, practices, roles and\nfunctions, resources, service outcomes and how outcomes will be measured\n■ Ensure that enough resources are allocated to the health service organisation’s risk\nmanagement system\n■ Foster an organisational culture that focuses on quality clinical trial service provision and\ncontinuous improvement in identifying and managing risk\n■ Incorporate systematic audits of safety and quality systems relating to clinical trial service provision\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n\n### Role and Functions\n\n- MBS items 82000, 82005, 82010, 82030, 93032, 93033, 93040 or 93041 provide a dual function for this purpose.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 65]\nMBS items 82000, 82005, 82010, 82030, 93032[BJ1] , 93033, 93040 or 93041 provide a dual function for this\npurpose.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 112]\nTerm Definition\nSite A facility, location or institution (or group of institutions) that resource,\nconduct and manage clinical trials that come under one of the final\nresearch authorisation sign off.98\nSponsor An individual, organisation or group taking on responsibility for securing\nthe arrangements to initiate, manage and finance a study.27\nStandard A standard agreed attributes and processes designed to ensure that a\nproduct, service or method will perform consistently at a designated level.93\nSystem The system is the resources, policies, processes and procedures that\nare organised, integrated, regulated and administered to accomplish a\nstated goal.\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [Page 21]\nRoles and functions\nof identified positions\nThe roles and functions relating to identified Health service organisations and trial sites may\npositions are consistent with the roles and also benefit from ensuring appropriate linkages\nfunctions of individuals in health service to the Central Points of Contact being established\norganisations undertaking clinical trials as in each jurisdiction to improve overall system\noutlined the Australian clinical trial handbook V2.1 navigation for sponsors and participants, to\n20187; the National Statement; Statement on streamline trial processes and time to trial\nConsumer and Community Participation in start-up; and improve workforce capacity under\nHealth and Medical Research9,30 and state and the (then) Council of Australian Governments\nterritory policies.31,32,33,34,35,36 Health Council revitalised clinical trials agenda\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [pages 46,47,48]\nrocedures and protocols that define a vision, principles, objectives, practices, roles and\nfunctions, resources, service outcomes and how outcomes will be measured\n■ Ensure that enough resources are allocated to the health service organisation’s risk\nmanagement system\n■ Foster an organisational culture that focuses on quality clinical trial service provision and\ncontinuous improvement in identifying and managing risk\n■ Incorporate systematic audits of safety and quality systems relating to clinical trial service provision\nin the whole-of-organisation audit program\n■ Ensure availability of data and information to support quality assurance and review of clinical trial\nservices across the health service organisation or trial site\n42 | Australian Commission on Safety and Quality in Health Care\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- Roles and functions of the clinical trial workforce\n■ Study coordination, data collection and data management\n■ Participant recruitment and enrolment\n■ Obtaining consent from prospective participants\n■ Undertaking study visits with trial participants, and collect and record information\nfrom research participants\n■ Maintain consistent study implementation\n■ Handling specimens\n■ Data management\n■ Dispensing and administering the investigational product\n■ Compliance with regulatory and reporting requirements\n■ Screen and recruit trial participants\n■ Deliver concomitant care (with responsibility aligned to clinical governance)\n■ Contribute to organisational data collection on clinical trial operations as required\nby the health service organisation.\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n\n### Strategic Priorities\n\n- The MDS provides a series of baseline operational metrics (indicators) relevant to national priority indicators and regulatory requirements, such as those provided in Actions 1.1, 1.8 and 1.9 of the NCTGF, in addition to workforce and trial participant experience.\n  Source: `pages/strategies-index__16.html (https://www.safetyandquality.gov.au/national-standards/clinical-trials-governance-framework/resources-national-clinical-trials-governance-framework)`\n- MBS items 82000, 82005, 82010, 82030, 93032, 93033, 93040 or 93041 provide a dual function for this purpose.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 65]\nMBS items 82000, 82005, 82010, 82030, 93032[BJ1] , 93033, 93040 or 93041 provide a dual function for this\npurpose.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.32 Interview of Person other than a Patient by Consultant Psychiatrist (Items 341, 343, 345,\n347, 349, 91874 to 91878 and 91882 to 91884)\nIntention of these items:\nItems 341, 343, 345, 347 and 349 and telehealth equivalent items 91874 to 91878 and 91882 to 91884 are for the\npurpose of interviews with patient relatives or close associates to investigate the particular problem with which the\npatient presented or the interaction between the patient and the person interviewed.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- Details of the requirements for a\nhealth assessment for each patient cohort are at:\n• Type 2 diabetes risk evaluation (40-49 years) – see AN.0.37.\n• Health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease –\nsee AN.0.38.\n• Health Assessment provided for people aged 75 years and older – see AN.0.39.\n• Health Assessment provided as a comprehensive medical assessment for residents of residential aged care\nfacilities – see AN.0.40.\n• Health Assessment provided for people with an intellectual disability – see AN.0.41.\n• Health Assessment provided for refugees and other humanitarian entrants – see AN.0.42.\n• One-off health assessment for veterans – see AN.0.69.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- For example, a 42 year old patient with an\nintellectual disability who is also found to be at high risk of developing type 2 diabetes as determined by the\nAustralian Type 2 Diabetes Risk Assessment Tool can receive:\n• a health assessment for a person with an intellectual disability annually, and\n• a type 2 diabetes risk evaluation every 3 years until they are 49 (inclusive).\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 74]\nAny patient who is eligible to receive Medicare benefits and meets the criteria for one or more of the following\ntarget groups may receive a health assessment service, at the stated frequencies:\nTarget Group Frequency of Service Associated Note\nA type 2 diabetes risk evaluation for people\naged 40-49 years (inclusive) with a high risk of\nOnce every three years to an eligible\ndeveloping type 2 diabetes as determined by the AN.0.37\npatient\nAustralian Type 2 Diabetes Risk Assessment\nTool\nA health assessment for people aged 45-49\nyears (inclusive) who are at risk of developing Once only to an eligible patient AN.0.38\nchronic disease\nA health assessment for people aged 75 years\nProvided annually to an eligible patient AN.0.39\nand older\nA comprehensive medical assessment for\npermanent residents of residential aged care Provided annually to an eligible patient AN.0.40\nfacilities\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.37 Time-tiered Health Assessment - Type 2 Diabetes Risk Evaluation\nPublication date: 1 July 2024\nSUMMARY\nTime-tiered health assessment items may be used to undertake a Type 2 Diabetes Risk Evaluation for Medicare\neligible patients aged 40-49 years (inclusive) with a high risk of developing type 2 diabetes.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.38 Time-Tiered Health Assessment - People aged 45-49 years who are at risk of developing\nchronic disease\nPublication date: 1 July 2024\nSUMMARY\nTime-tiered health assessment items may be used to undertake a health assessment for people aged 45-49 years\n(inclusive) who are at risk of developing chronic disease.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- A relevant visa means any of the following visas granted under the Migration Act 1958:\n• Subclass 070 Bridging (Removal Pending) visa\n• Subclass 200 (Refugee) visa\n• Subclass 201 (In-country Special Humanitarian) visa\n• Subclass 202 (Global Special Humanitarian) visa\n• Subclass 203 (Emergency Rescue) visa\n• Subclass 204 (Woman at Risk) visa\n• Subclass 786 (Temporary (Humanitarian Concern)) visa\n• Subclass 790 (Safe Haven Enterprise) visa\n• Subclass 866 (Protection) visa\nA health assessment provided for a refugee or other humanitarian entrant may only be claimed once by an eligible\npatient.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n\n## KPIs, Targets, and Where They Are At\n\n- [Page 74]\nAny patient who is eligible to receive Medicare benefits and meets the criteria for one or more of the following\ntarget groups may receive a health assessment service, at the stated frequencies:\nTarget Group Frequency of Service Associated Note\nA type 2 diabetes risk evaluation for people\naged 40-49 years (inclusive) with a high risk of\nOnce every three years to an eligible\ndeveloping type 2 diabetes as determined by the AN.0.37\npatient\nAustralian Type 2 Diabetes Risk Assessment\nTool\nA health assessment for people aged 45-49\nyears (inclusive) who are at risk of developing Once only to an eligible patient AN.0.38\nchronic disease\nA health assessment for people aged 75 years\nProvided annually to an eligible patient AN.0.39\nand older\nA comprehensive medical assessment for\npermanent residents of residential aged care Provided annually to an eligible patient AN.0.40\nfacilities\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- Potential consequence of improperly issuing an account\nThe potential consequences for improperly issuing an account are\n(a) No Medicare benefits will be paid for the service;\n(b) The medical practitioner who issued the account, or authorised its issue, may face charges under sections\n128A or 128B of the Health Insurance Act 1973.\n(c) Medicare benefits paid as a result of a false or misleading statement will be recoverable from the doctor\nunder section 129AC of the Health Insurance Act 1973.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- A locum must use the provider number allocated to the location if\n(a) they are an approved general practice or specialist trainee with a provider number issued for an approved training\nplacement; or\n(b) they are associated with an approved rural placement under Section 3GA of the Health Insurance Act 1973; or\n(c) they have access to Medicare benefits as a result of the issue of an exemption under section 19AB of the Health\nInsurance Act 1973 (i.e. they have access to Medicare benefits at specific practice locations); or\n(d) they will be at a practice which is participating in the Practice Incentives Program; or\n(e) they are associated with a placement on the MedicarePlus for Other Medical Practitioners (OMPs) program, the\nAfter Hours OMPs program, the Rural OMPs program or Outer Metropolitan OMPs program.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 62]\nSuggested strategies to meet this action\nGCP training may be achieved through a class or course, academic training program, or certification\nfrom a recognised clinical research professional organisation.49 In Australia, low cost and no cost GCP\ntraining programs are being promoted, developed and provided by some state health departments;50\nresearch institute member organisations51 and by health service organisations.52\nGCP training should be refreshed at least every three years in order to remain current with\nregulations, and guidelines and both the individual and the health service organisation are expected to\nretain GCP training documentation.\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- MBS items 82000, 82005, 82010, 82030, 93032, 93033, 93040 or 93041 provide a dual function for this purpose.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 65]\nMBS items 82000, 82005, 82010, 82030, 93032[BJ1] , 93033, 93040 or 93041 provide a dual function for this\npurpose.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.32 Interview of Person other than a Patient by Consultant Psychiatrist (Items 341, 343, 345,\n347, 349, 91874 to 91878 and 91882 to 91884)\nIntention of these items:\nItems 341, 343, 345, 347 and 349 and telehealth equivalent items 91874 to 91878 and 91882 to 91884 are for the\npurpose of interviews with patient relatives or close associates to investigate the particular problem with which the\npatient presented or the interaction between the patient and the person interviewed.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- Details of the requirements for a\nhealth assessment for each patient cohort are at:\n• Type 2 diabetes risk evaluation (40-49 years) – see AN.0.37.\n• Health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease –\nsee AN.0.38.\n• Health Assessment provided for people aged 75 years and older – see AN.0.39.\n• Health Assessment provided as a comprehensive medical assessment for residents of residential aged care\nfacilities – see AN.0.40.\n• Health Assessment provided for people with an intellectual disability – see AN.0.41.\n• Health Assessment provided for refugees and other humanitarian entrants – see AN.0.42.\n• One-off health assessment for veterans – see AN.0.69.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- For example, a 42 year old patient with an\nintellectual disability who is also found to be at high risk of developing type 2 diabetes as determined by the\nAustralian Type 2 Diabetes Risk Assessment Tool can receive:\n• a health assessment for a person with an intellectual disability annually, and\n• a type 2 diabetes risk evaluation every 3 years until they are 49 (inclusive).\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.37 Time-tiered Health Assessment - Type 2 Diabetes Risk Evaluation\nPublication date: 1 July 2024\nSUMMARY\nTime-tiered health assessment items may be used to undertake a Type 2 Diabetes Risk Evaluation for Medicare\neligible patients aged 40-49 years (inclusive) with a high risk of developing type 2 diabetes.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.38 Time-Tiered Health Assessment - People aged 45-49 years who are at risk of developing\nchronic disease\nPublication date: 1 July 2024\nSUMMARY\nTime-tiered health assessment items may be used to undertake a health assessment for people aged 45-49 years\n(inclusive) who are at risk of developing chronic disease.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- A relevant visa means any of the following visas granted under the Migration Act 1958:\n• Subclass 070 Bridging (Removal Pending) visa\n• Subclass 200 (Refugee) visa\n• Subclass 201 (In-country Special Humanitarian) visa\n• Subclass 202 (Global Special Humanitarian) visa\n• Subclass 203 (Emergency Rescue) visa\n• Subclass 204 (Woman at Risk) visa\n• Subclass 786 (Temporary (Humanitarian Concern)) visa\n• Subclass 790 (Safe Haven Enterprise) visa\n• Subclass 866 (Protection) visa\nA health assessment provided for a refugee or other humanitarian entrant may only be claimed once by an eligible\npatient.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- Australian Hospital Survey on Patient Safety Culture (A-HSOPS) 2.0\nOur Australian Hospital Survey on Patient Safety Culture (A-HSOPS 2.0) provides hospitals with a staff survey to measure and improve on patient safety culture.\n  Source: `pages/strategies-index__11.html (https://www.safetyandquality.gov.au/data-and-measurement/patient-safety-culture)`\n- [pages 56,57]\nis by no means an\nexhaustive list) :-\n- hospital visits where a physical examination does not result, or where only a limited examination is\nperformed;\n- hospital visits where a significant alteration to the therapy or overall management plan does not ensue;\n- brief consultations or hospital visits not involving subsequent discussions regarding patient's progress\nwith a specialist colleague or the referring practitioner.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| $30, , $30\n, $110, , $85, , $25 | However, as the EMSN benefit cap is $30, only $30\nwill be paid.\no If the fee charged by the doctor for Item A is $110, the standard Medicare rebate is $85, with an out-of-pocket cost\nof $25. | `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)` |\n\n## Key Achievements\n\n- These shared ways of ■ Clear responsibilities for managing high-\nthinking are then translated into common and quality clinical trial services and appropriate\nrepeated patterns of behaviour: patterns of delegation of the necessary management\nbehaviour that are in turn maintained and authority for this purpose\nreinforced by the rituals, ceremonies and\n■ Reliable processes for ensuring that systems\nrewards of everyday organisational life.24\nfor delivering clinical trials perform well, and\nFactors that have been identified as being clinicians are fully engaged in the design,\nimportant for sustaining cultures that ensure monitoring and development of these\nclinical trials are delivered in a high-quality systems\nmanner and promote safety standards ■ Effective use of data and information to\ninclude:25,26 monitor and report on operational\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [pages 14,15,16,17]\nvement\n■ Translating the vision into clear objectives for ■ Well-designed systems for identifying,\nsafety and quality at all levels of the quantifying, and managing risk\norganisation, and establishing measures to ■ Opportunities for consumer engagement in\nassess progress the design of clinical trial services and\n■ Providing a supportive and positive working processes that supports consumer\nenvironment for the workforce engagement as a part of the health service\norganisation strategic plan.\n■ Ensuring that members of the workforce are\nengaged in their work\n■ Having an organisation that is transparent\nabout performance, open to learning and\ncontinuously improving\n■ Supporting multidisciplinary teams to work\ntogether effectively.\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- MBS items 82000, 82005, 82010, 82030, 93032, 93033, 93040 or 93041 provide a dual function for this purpose.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 65]\nMBS items 82000, 82005, 82010, 82030, 93032[BJ1] , 93033, 93040 or 93041 provide a dual function for this\npurpose.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.26 Geriatrician Referred Patient Assessment and Management Plan (Items 141-147)\nItems 141 -147 apply only to services provided by a consultant physician or specialist in the specialty of Geriatric\nMedicine who has completed the additional requirements of the Royal Australasian College of Physicians for\nrecognition in the subspecialty of geriatric medicine.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.32 Interview of Person other than a Patient by Consultant Psychiatrist (Items 341, 343, 345,\n347, 349, 91874 to 91878 and 91882 to 91884)\nIntention of these items:\nItems 341, 343, 345, 347 and 349 and telehealth equivalent items 91874 to 91878 and 91882 to 91884 are for the\npurpose of interviews with patient relatives or close associates to investigate the particular problem with which the\npatient presented or the interaction between the patient and the person interviewed.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- Details of the requirements for a\nhealth assessment for each patient cohort are at:\n• Type 2 diabetes risk evaluation (40-49 years) – see AN.0.37.\n• Health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease –\nsee AN.0.38.\n• Health Assessment provided for people aged 75 years and older – see AN.0.39.\n• Health Assessment provided as a comprehensive medical assessment for residents of residential aged care\nfacilities – see AN.0.40.\n• Health Assessment provided for people with an intellectual disability – see AN.0.41.\n• Health Assessment provided for refugees and other humanitarian entrants – see AN.0.42.\n• One-off health assessment for veterans – see AN.0.69.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- For example, a 42 year old patient with an\nintellectual disability who is also found to be at high risk of developing type 2 diabetes as determined by the\nAustralian Type 2 Diabetes Risk Assessment Tool can receive:\n• a health assessment for a person with an intellectual disability annually, and\n• a type 2 diabetes risk evaluation every 3 years until they are 49 (inclusive).\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 74]\nAny patient who is eligible to receive Medicare benefits and meets the criteria for one or more of the following\ntarget groups may receive a health assessment service, at the stated frequencies:\nTarget Group Frequency of Service Associated Note\nA type 2 diabetes risk evaluation for people\naged 40-49 years (inclusive) with a high risk of\nOnce every three years to an eligible\ndeveloping type 2 diabetes as determined by the AN.0.37\npatient\nAustralian Type 2 Diabetes Risk Assessment\nTool\nA health assessment for people aged 45-49\nyears (inclusive) who are at risk of developing Once only to an eligible patient AN.0.38\nchronic disease\nA health assessment for people aged 75 years\nProvided annually to an eligible patient AN.0.39\nand older\nA comprehensive medical assessment for\npermanent residents of residential aged care Provided annually to an eligible patient AN.0.40\nfacilities\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.37 Time-tiered Health Assessment - Type 2 Diabetes Risk Evaluation\nPublication date: 1 July 2024\nSUMMARY\nTime-tiered health assessment items may be used to undertake a Type 2 Diabetes Risk Evaluation for Medicare\neligible patients aged 40-49 years (inclusive) with a high risk of developing type 2 diabetes.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- The Australian Type 2 Diabetes Risk Assessment Tool must have been completed by the patient no more than 3\nmonths prior to the Type 2 Diabetes Risk Evaluation.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.38 Time-Tiered Health Assessment - People aged 45-49 years who are at risk of developing\nchronic disease\nPublication date: 1 July 2024\nSUMMARY\nTime-tiered health assessment items may be used to undertake a health assessment for people aged 45-49 years\n(inclusive) who are at risk of developing chronic disease.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n\n## Key Issues, Risks, and Recommendations\n\n- The detailed Management Plan should contain:\n• The findings of the comprehensive diagnostic assessment and the formulation that contributed to this\nassessment (including the finding of the outcome tools where clinically appropriate)\n• Relevant history and Mental Status Examination\n• Identification of any risks to the patient or others\n• Detailed management plan which includes, as clinically appropriate, not limited to one or more of the\nfollowing recommendations:\no Biopsychosocial management\no Non-medication recommendations including (where relevant): psychoeducation; recommendations for\npsychological treatment (and who should provide this); social prescribing\no Indications for review or episode and escalation of treatment strategies\no Longer term management goals\nReview of Management Plan - Item 293 or 92436:\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [pages 46,47,48]\nrocedures and protocols that define a vision, principles, objectives, practices, roles and\nfunctions, resources, service outcomes and how outcomes will be measured\n■ Ensure that enough resources are allocated to the health service organisation’s risk\nmanagement system\n■ Foster an organisational culture that focuses on quality clinical trial service provision and\ncontinuous improvement in identifying and managing risk\n■ Incorporate systematic audits of safety and quality systems relating to clinical trial service provision\nin the whole-of-organisation audit program\n■ Ensure availability of data and information to support quality assurance and review of clinical trial\nservices across the health service organisation or trial site\n42 | Australian Commission on Safety and Quality in Health Care\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [Page 69]\nExamples of evidence\n■ Policy documents that describe the health service organisation’s requirements for maintaining\nbuildings, plant, equipment, utilities and devices required to deliver clinical trial services\n■ Strategic plan for facilities and capital works\n■ Maintenance schedule for buildings, equipment, utilities and devices\n■ Audit results of compliance with maintenance schedules and inspections of equipment\n■ Register of equipment that is assigned to meet individual trial participants needs\n■ Risk assessment to identify suitability of all new equipment\n■ Observation of design and use of the environment to reduce risks relating to self-harm (for\nexample, removal of ligature points, collapsible curtain rails)\n■ Observation that the physical environment includes consideration of safety and quality (for\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- Audit and Risk Committee\nThe Audit and Risk Committee (ARC) has been established by the Board in compliance with section 45 of the\nPublic Governance, Performance and Accountability Act 2013 (PGPA Act)\nand the\nPublic Governance, Performance and Accountability Rule (PGPA Rule)\nsection 17: Audit Committees for Commonwealth Entities.\n  Source: `pages/about.html (https://www.safetyandquality.gov.au/about-us/committees)`\n- Development of the Treatment and Management Plan\nOnce the paediatrician has made a diagnosis of a complex neurodevelopmental disorder, to complete the item\nrequirements of item 135 or 92140 they must develop a treatment and management plan which includes:\nWritten documentation of the patient’s confirmed diagnosis of a complex neurodevelopmental disorder, including\nany findings of assessments performed (which assisted with the formulation of the diagnosis or contributed to the\ntreatment and management plan)\n• A risk assessment which means assessment of:\no the risk to the patient of a contributing co-morbidity and\no environmental, physical, social and emotional risk factors that may apply to the patient or to\nanother individual.\n• Treatment options which include:\no Recommendations using a biopsychosocial model\no Identify major treatment goals and important milestones and objectives\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- Development of the treatment and management plan\nOnce the specialist or consultant physician has made a diagnosis of an eligible disability, to complete the item\nrequirements of item 137 or 92141 they must develop a treatment and management plan which includes:\n• Written documentation of the patient’s confirmed diagnosis of an eligible disability, including any findings\nof assessments performed (which assisted with the formulation of the diagnosis or contributed to the\ntreatment and management plan)\n• A risk assessment which means assessment of:\no the risk to the patient of a contributing co-morbidity and\no environmental, physical, social and emotional risk factors that may apply to the patient or to another\nindividual.\n• Treatment options which:\no Recommendations using a biopsychosocial model\no Identify major treatment goals and important milestones and objectives\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- Details of the requirements for a\nhealth assessment for each patient cohort are at:\n• Type 2 diabetes risk evaluation (40-49 years) – see AN.0.37.\n• Health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease –\nsee AN.0.38.\n• Health Assessment provided for people aged 75 years and older – see AN.0.39.\n• Health Assessment provided as a comprehensive medical assessment for residents of residential aged care\nfacilities – see AN.0.40.\n• Health Assessment provided for people with an intellectual disability – see AN.0.41.\n• Health Assessment provided for refugees and other humanitarian entrants – see AN.0.42.\n• One-off health assessment for veterans – see AN.0.69.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- For example, a 42 year old patient with an\nintellectual disability who is also found to be at high risk of developing type 2 diabetes as determined by the\nAustralian Type 2 Diabetes Risk Assessment Tool can receive:\n• a health assessment for a person with an intellectual disability annually, and\n• a type 2 diabetes risk evaluation every 3 years until they are 49 (inclusive).\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 74]\nAny patient who is eligible to receive Medicare benefits and meets the criteria for one or more of the following\ntarget groups may receive a health assessment service, at the stated frequencies:\nTarget Group Frequency of Service Associated Note\nA type 2 diabetes risk evaluation for people\naged 40-49 years (inclusive) with a high risk of\nOnce every three years to an eligible\ndeveloping type 2 diabetes as determined by the AN.0.37\npatient\nAustralian Type 2 Diabetes Risk Assessment\nTool\nA health assessment for people aged 45-49\nyears (inclusive) who are at risk of developing Once only to an eligible patient AN.0.38\nchronic disease\nA health assessment for people aged 75 years\nProvided annually to an eligible patient AN.0.39\nand older\nA comprehensive medical assessment for\npermanent residents of residential aged care Provided annually to an eligible patient AN.0.40\nfacilities\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.37 Time-tiered Health Assessment - Type 2 Diabetes Risk Evaluation\nPublication date: 1 July 2024\nSUMMARY\nTime-tiered health assessment items may be used to undertake a Type 2 Diabetes Risk Evaluation for Medicare\neligible patients aged 40-49 years (inclusive) with a high risk of developing type 2 diabetes.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- AN.0.38 Time-Tiered Health Assessment - People aged 45-49 years who are at risk of developing\nchronic disease\nPublication date: 1 July 2024\nSUMMARY\nTime-tiered health assessment items may be used to undertake a health assessment for people aged 45-49 years\n(inclusive) who are at risk of developing chronic disease.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- A relevant visa means any of the following visas granted under the Migration Act 1958:\n• Subclass 070 Bridging (Removal Pending) visa\n• Subclass 200 (Refugee) visa\n• Subclass 201 (In-country Special Humanitarian) visa\n• Subclass 202 (Global Special Humanitarian) visa\n• Subclass 203 (Emergency Rescue) visa\n• Subclass 204 (Woman at Risk) visa\n• Subclass 786 (Temporary (Humanitarian Concern)) visa\n• Subclass 790 (Safe Haven Enterprise) visa\n• Subclass 866 (Protection) visa\nA health assessment provided for a refugee or other humanitarian entrant may only be claimed once by an eligible\npatient.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- For example, people at all levels of\norganisational plans and strategies. a health service organisation may be involved in\nThe governing body also endorses and approves the design and implementation of risk\nbudgets, and major financial and organisational management, performance monitoring and audit\ndecisions, and: programs, which are key elements of good\n■ Ensures that the organisation is being governance systems.\nproperly managed, including that\n− systems of production or service delivery\nare well designed and fit for purpose\n− services meet desired standards\n− the organisation meets its compliance\nobligations\n■ Challenges the assumptions of management\n■ Reviews and monitoring performance of the\ncontrol framework to ensure that major risks\nare identified and managed\n■ Ensures that there is an ongoing focus on\nquality improvement\n■ Evaluates reports, and reviewing feedback,\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [pages 12,13,14]\nrganisation is being governance systems.\nproperly managed, including that\n− systems of production or service delivery\nare well designed and fit for purpose\n− services meet desired standards\n− the organisation meets its compliance\nobligations\n■ Challenges the assumptions of management\n■ Reviews and monitoring performance of the\ncontrol framework to ensure that major risks\nare identified and managed\n■ Ensures that there is an ongoing focus on\nquality improvement\n■ Evaluates reports, and reviewing feedback,\nsuggestions and complaints\n■ Ensures the continuing development of the\nexecutive management team\n■ Plans for succession\n■ Communicates with, and is accountable to,\npatients and consumers and, internal and\nexternal stakeholders.\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n\n## Corporate Values and Operating Culture\n\n- Features commonly include acknowledgement of the high-risk, error-\nprone nature of an organisation’s activities; a blame-free environment in\nwhich individuals are able to report errors or near misses without fear\nof reprimand or punishment; an expectation of collaboration across all\nareas and levels of an organisation to seek solutions to vulnerabilities;\nand a willingness of the organisation to direct resources to deal with\nsafety concerns.97\nScope of clinical Scope of clinical practice the extent of an individual clinician’s approved\npractice clinical practice within a particular organisation, based on the clinician’s\nskills, knowledge, performance and professional suitability, and the needs\nand service capability of the organisation.27\nSafety Events A serious adverse event (experience) or reaction is any untoward medical\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [pages 111,112,113,114]\nnt; an expectation of collaboration across all\nareas and levels of an organisation to seek solutions to vulnerabilities;\nand a willingness of the organisation to direct resources to deal with\nsafety concerns.97\nScope of clinical Scope of clinical practice the extent of an individual clinician’s approved\npractice clinical practice within a particular organisation, based on the clinician’s\nskills, knowledge, performance and professional suitability, and the needs\nand service capability of the organisation.27\nSafety Events A serious adverse event (experience) or reaction is any untoward medical\noccurrence that at any dose results in death or is life threatening.80\nThe National Clinical Trials Governance Framework and user guide for health service organisations conducting clinical trials | 107\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- The requirement of \"personal performance\" is met whether or not essential assistance is provided,\naccording to accepted medical practice:-\n(a) Category 1 (Professional Attendances) items except 170-172, 342-346, 820-880, 6029–6042, 6064-6075;\n(b) Each of the following items in Group D1 (Miscellaneous Diagnostic):- 11012, 11015, 11018, 11021, 11304,\n11600, 11627, 11705, 11724, 11728, 11729, 11730, 11731, 11921, 12000, 12003;\n(c) All Group T1 (Miscellaneous Therapeutic) items (except 13020, 13025, 13200-13206, 13212-13221, 13703,\n13706, 13750-13760, 13950, 14050, 14221 and 14245);\n(d) Item 15600 in Group T2 (Radiation Oncology);\n(e) All Group T3 (Therapeutic Nuclear Medicine) items;\n(f) All Group T4 (Obstetrics) items (except 16400 and 16514);\n(g) All Group T6 (Anaesthetics) items;\n(h) All Group T7 (Regional or Field Nerve Block) items;\n(i) All Group T8 (Operations) items;\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 62]\nSuggested strategies to meet this action\nGCP training may be achieved through a class or course, academic training program, or certification\nfrom a recognised clinical research professional organisation.49 In Australia, low cost and no cost GCP\ntraining programs are being promoted, developed and provided by some state health departments;50\nresearch institute member organisations51 and by health service organisations.52\nGCP training should be refreshed at least every three years in order to remain current with\nregulations, and guidelines and both the individual and the health service organisation are expected to\nretain GCP training documentation.\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [pages 95,96]\nunder the Clinical Trial Notifiation\nnon-industry sponsors reported by international (CTN) and Clinical Trial Approval (CTA) schemes\nregulators.76,78 in Australia, the TGA also provide the annotated\nGuidance for Good Clinical Practice (2016) and\nHowever, health service organisations have a\nguidance materials including the Australian\nresponsibility to protect the safety and welfare\nclinical trial handbook (2018).7\nof participants who may also be cared for\nwithin their health service organisation and\nas such, should ensure training in GCP for the\nintegrity of their research programs and their\nresearchers and the individual projects that\nthose researchers conduct.\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n- [pages 41,42]\nevaluating the patient’s condition or conditions including, if applicable, evaluation using a health\nscreening service mentioned in subsection 19(5) of the [Health Insurance] Act\n• formulating a plan for the management and, if applicable, for the treatment of the patient’s condition or\nconditions\n• giving advice to the patient about the patient’s condition or conditions and, if applicable, about treatment\n• if authorised by the patient—giving advice to another person, or other persons, about the patient’s\ncondition or conditions and, if applicable, about treatment\n• providing appropriate preventive health care\n• recording the clinical details of the service or services provided to the patient.”\nFurther information on professional attendances is at AN.0.3.\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- [Page 74]\nAny patient who is eligible to receive Medicare benefits and meets the criteria for one or more of the following\ntarget groups may receive a health assessment service, at the stated frequencies:\nTarget Group Frequency of Service Associated Note\nA type 2 diabetes risk evaluation for people\naged 40-49 years (inclusive) with a high risk of\nOnce every three years to an eligible\ndeveloping type 2 diabetes as determined by the AN.0.37\npatient\nAustralian Type 2 Diabetes Risk Assessment\nTool\nA health assessment for people aged 45-49\nyears (inclusive) who are at risk of developing Once only to an eligible patient AN.0.38\nchronic disease\nA health assessment for people aged 75 years\nProvided annually to an eligible patient AN.0.39\nand older\nA comprehensive medical assessment for\npermanent residents of residential aged care Provided annually to an eligible patient AN.0.40\nfacilities\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)`\n- These shared ways of ■ Clear responsibilities for managing high-\nthinking are then translated into common and quality clinical trial services and appropriate\nrepeated patterns of behaviour: patterns of delegation of the necessary management\nbehaviour that are in turn maintained and authority for this purpose\nreinforced by the rituals, ceremonies and\n■ Reliable processes for ensuring that systems\nrewards of everyday organisational life.24\nfor delivering clinical trials perform well, and\nFactors that have been identified as being clinicians are fully engaged in the design,\nimportant for sustaining cultures that ensure monitoring and development of these\nclinical trials are delivered in a high-quality systems\nmanner and promote safety standards ■ Effective use of data and information to\ninclude:25,26 monitor and report on operational\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)`\n\n## Global Ideas and Case Study Inputs\n\n_No global-intelligence source text found yet. Run `CLAUDE/global-ideas-scraper.py <entity>` to populate case-study sources._\n\n## Source Artifacts Used\n\n- `strategies/Manchester-Patient-Safety-Framework.pdf` - strategies - https://www.ajustnhs.com/wp-content/uploads/2012/10/Manchester-Patient-Safety-Framework.pdf\n- `pages/about.html` - pages - https://www.safetyandquality.gov.au/about-us/committees\n- `pages/homepage.html` - pages - https://www.safetyandquality.gov.au/about-us/committees#primary-care-committee\n- `pages/news-latest.html` - pages - https://www.safetyandquality.gov.au/news-and-media\n- `pages/strategies-index.html` - pages - https://www.safetyandquality.gov.au/national-standards/national-clinical-trials-governance-framework\n- `pages/strategies-index__00.html` - pages - https://www.safetyandquality.gov.au/national-standards/national-clinical-trials-governance-framework\n- `pages/strategies-index__01.html` - pages - https://www.safetyandquality.gov.au/sites/default/files/2025-07-favicon.png\n- `pages/strategies-index__02.html` - pages - https://www.safetyandquality.gov.au/national-standards/national-safety-and-quality-digital-mental-health-standards\n- `pages/strategies-index__03.html` - pages - https://www.safetyandquality.gov.au/accreditation/assessment-outcomes-data\n- `pages/strategies-index__04.html` - pages - https://www.safetyandquality.gov.au/clinical-topics/digital-health\n- `pages/strategies-index__05.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement\n- `pages/strategies-index__06.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement/australian-atlas-healthcare-variation\n- `pages/strategies-index__07.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement/case-studies\n- `pages/strategies-index__08.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement/clinical-quality-registries\n- `pages/strategies-index__09.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement/medicineinsight\n- `pages/strategies-index__10.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement/patient-reported-measures\n- `pages/strategies-index__11.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement/patient-safety-culture\n- `pages/strategies-index__12.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement/practice-reflections\n- `pages/strategies-index__13.html` - pages - https://www.safetyandquality.gov.au/data-and-measurement/safety-and-quality-measures\n- `pages/strategies-index__14.html` - pages - https://www.safetyandquality.gov.au/resources/national-clinical-trials-governance-framework-and-user-guide\n- `pages/strategies-index__15.html` - pages - https://www.safetyandquality.gov.au/national-standards/clinical-trials-governance-framework/about-national-clinical-trials-governance-framework\n- `pages/strategies-index__16.html` - pages - https://www.safetyandquality.gov.au/national-standards/clinical-trials-governance-framework/resources-national-clinical-trials-governance-framework\n- `pages/strategies-index__17.html` - pages - https://www.safetyandquality.gov.au/national-standards/clinical-trials-governance-framework/assessment-national-clinical-trials-governance-framework\n- `pages/strategies-index__18.html` - pages - https://www.safetyandquality.gov.au/accreditation/assessment-outcomes-data/assessment-outcomes-data-clinical-trial-services\n- `pages/strategies-index__19.html` - pages - https://www.safetyandquality.gov.au/webform/ajax/feedback?target_id=feedback-form-replace&page_path=/national-standards/national-clinical-trials-governance-framework\n- `pages/structure.html` - pages - https://www.safetyandquality.gov.au/national-standards/national-safety-and-quality-mental-health-standards-community-managed-organisations\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf` - other-pdfs - https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf\n- `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf` - other-pdfs - https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf\n\n## Gaps To Fix\n\n- No corporate plan text source found.\n- No annual report text source found.\n- No global comparison/case-study sources found.",
  "legislation_md": "# Australian Commission on Safety and Quality in Health Care's Primary Care Commit - Acts and Legislation Discovery\n\n**Generated at**: 2026-05-09T21:10:18.054935+00:00\n**Entity ID**: B-002552\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n\n> This is an evidence-based discovery list from scraped department material. A mention does not always mean the department administers the legislation; high-confidence and official register links should be reviewed.\n\n## Summary\n\n- Source files scanned: 28\n- Unique legislation references found: 19\n\n| Type | Count |\n|---|---:|\n| Act | 9 |\n| Determination | 2 |\n| Regulation | 6 |\n| Rules | 2 |\n\n## Legislation References\n\n### Health Insurance Act 1973\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 48\n**Register search**: https://www.legislation.gov.au/search?query=Health+Insurance+Act+1973\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- ') provides access to medical and hospital services for all Australian residents and\ncertain categories of visitors to Australia. Services Australia administers Medicare and the payment of Medicare\nbenefits. The major elements of Medicare are contained in the Health Insurance Act 1973, as amended, and include\nthe following:\na. Free treatment for public patients in public hospitals.\nb. The payment of 'benefits', or rebates, for professional services listed in the Medicare Benefits Schedule\n(MBS). The relevant benefit rates are:\n7\n\n[page 8]\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- practitioner concerned.\n* MBS items 10988 and 10989 generally attract a 100% rebate but can be specified as 'Type C' treatments and\nattract a 75% rebate.\nGN.1.3 Medicare benefits and billing practices\nKey information on Medicare benefits and billing practices\nThe Health Insurance Act 1973 stipulates that Medicare benefits are payable for professional services. A\nprofessional service is a clinically relevant service which is listed in the MBS. A medical service is clinically\nrelevant if it is generally accepted in the medical profession as nece\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- n account\nThe potential consequences for improperly issuing an account are\n(a) No Medicare benefits will be paid for the service;\n(b) The medical practitioner who issued the account, or authorised its issue, may face charges under sections\n128A or 128B of the Health Insurance Act 1973.\n(c) Medicare benefits paid as a result of a false or misleading statement will be recoverable from the doctor\nunder section 129AC of the Health Insurance Act 1973.\nProviders should be aware that Services Australia is legally obliged to investigate doctors su\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- ssued the account, or authorised its issue, may face charges under sections\n128A or 128B of the Health Insurance Act 1973.\n(c) Medicare benefits paid as a result of a false or misleading statement will be recoverable from the doctor\nunder section 129AC of the Health Insurance Act 1973.\nProviders should be aware that Services Australia is legally obliged to investigate doctors suspected of making false\nor misleading statements, and may refer them for prosecution if the evidence indicates fraudulent charging to\nMedicare. If Medicare benefits\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- , or to provide services for or on behalf\nof another practitioner, practitioners must meet one of the following criteria:\n(a) be a recognised specialist, consultant physician or general practitioner; or\n(b) be in an approved placement under section 3GA of the Health Insurance Act 1973; or\n(c) be a temporary resident doctor with an exemption under section 19AB of the Health Insurance Act 1973, and\nworking in accord with that exemption.\nAny practitioner who does not satisfy the requirements outlined above may still practice medicine but thei\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Health Insurance (General Medical Services Table) Regulations 2021\n\n**Type**: Regulation\n**Confidence**: high\n**Mentions**: 19\n**Register search**: https://www.legislation.gov.au/search?query=Health+Insurance+%28General+Medical+Services+Table%29+Regulations+2021\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- . The Ahpra registration\nfor these medical practitioners will indicate that they are a specialist in the field of general practice.\n2. Medical practitioners on an Approved Placement in a general practice training program\nSection 1.1.3 of the Health Insurance (General Medical Services Table) Regulations 2021 provides access to the\nMBS GP items to medical practitioners undertaking an approved training placement. That is, a training placement\nthat will lead to fellowship with the RACGP or ACCRM.\n• For more information on approved training placements see the General\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- GPs to access MBS GP items provided they continue to be registered with Ahpra.\n4. Eligible non-vocationally recognised medical practitioners\nThe programs below closed to new participants on 1 January 2019.\n14\n\n[page 15]\nSection 1.1.2 of the Health Insurance (General Medical Services Table) Regulations 2021 specifies which non-\nvocationally recognised medical practitioners can access MBS GP items:\n1. Medical practitioners who have been notified by the Chief Executive of Medicare that they have completed\nthe requirements of the MedicarePlus for Other Medical Prac\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- the legislative arrangements applying to the categories of medical practitioners able to use the MBS GP\nitems can be found on the Federal Register of Legislation, and are set out in three regulatory instruments:\n• Health Insurance Act 1973\n• Health Insurance (General Medical Services Table) Regulations 2021\n• Health Insurance Regulations 2018\nGN.5.14 Recognition as a Specialist or Consultant Physician\nA medical practitioner who:\n· is registered as a specialist under State or Territory law; or\n· holds a fellowship of a specified specialist College and has obtaine\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- ically relevant and distinct\nservices.\nGeneral attendance items and chronic disease management items 229, 230, 233, 721, 723 and 732 cannot be claimed\non the same day for the same patient. This restriction is set out in clause 2.16.11 of the Health Insurance (General\nMedical Services Table) Regulations 2021.\nFurther information on co-claiming of general attendance items and other MBS items is available in the AskMBS\nAdvisory – General Practice Services #2.\nRECORD KEEPING AND REPORTING REQUIREMENTS\nThe department undertakes regular post payment auditing to ensure\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- 761, 763, 766, 769, 772, 776, 788, 789, 2197, 2198, 2200\n• Health Insurance (Section 3C General Medical Services – Telehealth and Telephone Attendances)\nDetermination 2021 – telehealth (video) and telephone attendance items.\n44\n\n[page 45]\n• Health Insurance (General Medical Services Table) Regulations 2021 – all other attendance items.\nAN.0.11 Derived fee items for general practice\nDerived fees apply to a range of attendance items that are used when services are provided outside of consulting\nrooms, including some MBS items used in residential aged care facilit\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### National Health Reform Act 2011\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 4\n**Register search**: https://www.legislation.gov.au/search?query=National+Health+Reform+Act+2011\n\n**Sources**:\n- `pages/about.html`\n- `pages/homepage.html`\n\n**Evidence contexts**:\n- nce, Performance and Accountability Act 2013 (PGPA Act)\nand the\nPublic Governance, Performance and Accountability Rule (PGPA Rule)\nsection 17: Audit Committees for Commonwealth Entities.\nThe Committee assists the Board discharge its responsibilities under the\nNational Health Reform Act 2011\nand the PGPA Act with respect to financial reporting, performance reporting, the system of risk oversight and management, and the system of internal control.\nMembership of the ARC:\nMs Jennifer Clark (Chair)\nMr Peter Achterstraat\nMs Lily Viertmann\nMr David Swa\n  Source: `pages/about.html`\n- e IJC was established as a key forum in 2012 for the Commission to engage with the jurisdictions under the Australian Commission on Safety and Quality in Health Care Intergovernment Agreement, after the Commission was established as a body corporate under the\nNational Health Reform Act 2011\n. The IJC is responsible for providing advice to the Commission on our policies, programs, standards, guidelines and indicators and the implementation of these; and the maintenance of effective working relationships with key stakeholders to facilitate the wor\n  Source: `pages/about.html`\n- nce, Performance and Accountability Act 2013 (PGPA Act)\nand the\nPublic Governance, Performance and Accountability Rule (PGPA Rule)\nsection 17: Audit Committees for Commonwealth Entities.\nThe Committee assists the Board discharge its responsibilities under the\nNational Health Reform Act 2011\nand the PGPA Act with respect to financial reporting, performance reporting, the system of risk oversight and management, and the system of internal control.\nMembership of the ARC:\nMs Jennifer Clark (Chair)\nMr Peter Achterstraat\nMs Lily Viertmann\nMr David Swa\n  Source: `pages/homepage.html`\n- e IJC was established as a key forum in 2012 for the Commission to engage with the jurisdictions under the Australian Commission on Safety and Quality in Health Care Intergovernment Agreement, after the Commission was established as a body corporate under the\nNational Health Reform Act 2011\n. The IJC is responsible for providing advice to the Commission on our policies, programs, standards, guidelines and indicators and the implementation of these; and the maintenance of effective working relationships with key stakeholders to facilitate the wor\n  Source: `pages/homepage.html`\n\n### Aged Care Act 1997\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 3\n**Register search**: https://www.legislation.gov.au/search?query=Aged+Care+Act+1997\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- r a single patient gap to apply. The Schedule fee for the service will be ascertained in\naccordance with the particular rules shown in the relevant items.\n32\n\n[page 33]\nGN.14.38 Residential aged care facility\nA residential aged care facility is defined in the Aged Care Act 1997; the definition includes facilities formerly\nknown as nursing homes and hostels.\nGN.15.39 Practitioners should maintain adequate and contemporaneous records\nAll practitioners who provide, or initiate, a service for which a Medicare benefit is payable, should\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- cal Assessment.\nELIGIBLE PATIENTS\nPatients eligible for a Comprehensive Medical Assessment are care recipients in a residential aged care facility. The\nRegulations define a care recipient as a person to whom residential care (as defined in section 41-3 of the Aged Care\nAct 1997) is provided.\nA Comprehensive Medical Assessment may be provided on admission to a residential aged care facility, if a\nComprehensive Medical Assessment has not already been provided to the patient in another residential aged care\nfacility in the last 12 mont\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- and packing and unpacking of equipment. The loading is in addition to\nthe consultation item. For the purposes of the loading, acceptable places of residence for domiciliary visits are:\n- the patient's home;\n- a residential aged care facility as defined by the Aged Care Act 1997; or\n- an institution which means a place (other than a residential aged care facility or hospital) at which\nresidential accommodation and/or day care is made available to any of the following categories: disadvantaged\nchildren, juvenile offenders, aged person\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Health Insurance (Professional Services Review) Regulations 1999\n\n**Type**: Regulation\n**Confidence**: high\n**Mentions**: 3\n**Register search**: https://www.legislation.gov.au/search?query=Health+Insurance+%28Professional+Services+Review%29+Regulations+1999\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- ttend and give evidence;\nrequire the production of documents (including clinical notes).\nThe methods available to a PSR Committee to investigate and quantify inappropriate practice are specified in\nlegislation:\n(a) Patterns of Services - The Health Insurance (Professional Services Review) Regulations 1999 specify that\nwhen a general practitioner or other medical practitioner reaches or exceeds 80 or more attendances on each of 20 or\nmore days in a 12-month period, they are deemed to have practiced inappropriately.\n21\n\n[page 22]\nA professional attendance means\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- mporaneous records. It will be up to the peer judgement of the PSR\nCommittee to decide if a practitioner's records meet the prescribed standards.\nThe standards which determine if a record is adequate and contemporaneous are prescribed in the Health Insurance\n(Professional Services Review) Regulations 1999.\nTo be adequate, the patient or clinical record needs to:\nclearly identify the name of the patient; and\ncontain a separate entry for each attendance by the patient for a service and the date on which the service was\nrendered or initiated; and\neach entry needs\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- us patient records. It will be up to the peer judgement of the PSR Committee to decide if a\npractitioner's records meet the prescribed standards.\nThe standards which determine if a record is adequate and contemporaneous are prescribed in the Health Insurance\n(Professional Services Review) Regulations 1999.\nTo be adequate, the patient or clinical record needs to:\nclearly identify the name of the patient; and\ncontain a separate entry for each attendance by the patient for a service and the date on which the service\nwas rendered or initiated; and\neach entry needs\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Social Security Act 1991\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 3\n**Register search**: https://www.legislation.gov.au/search?query=Social+Security+Act+1991\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- e examination or\ncollection;\n(e) a medical examination for a person as a prerequisite of that person becoming eligible to foster a child or children;\n(f) a medical or optometrical examination provided to a person who is an unemployed person (as defined by the\nSocial Security Act 1991), as the request of a prospective employer.\nThe National Policy for the National Cervical Screening Program (NCSP) is as follows:\n30\n\n[page 31]\n(a) Cervical screening should be undertaken every five years in asymptomatic persons, using a primary human\npapillo\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- has attained the age of 16 years who is in the custody, care and control of the person of the spouse of the person;\nor\n(ii) is receiving full time education at a school, college or university; and\n(iii) is not being paid a disability support pension under the Social Security Act 1991; and\n(iv) is wholly or substantially dependent on the person or on the spouse of the person.\nGN.14.34 Principles of interpretation of the MBS\nEach professional service listed in the MBS is a complete medical service. Where a listed service is also a\ncomponent\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- has attained the age of 16 years who is in the custody, care and control of the person of the spouse of the person;\nor\n(ii) is receiving full time education at a school, college or university; and\n(iii) is not being paid a disability support pension under the Social Security Act 1991; and\n(iv) is wholly or substantially dependent on the person or on the spouse of the person.\nAN.0.9 Using time-tiered professional (general) attendance items\nSUMMARY\nThis note sets out the key common principles that apply when using the time-tiered profession\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Health Insurance (General Medical Service Table) Regulations 2021\n\n**Type**: Regulation\n**Confidence**: medium\n**Mentions**: 2\n**Register search**: https://www.legislation.gov.au/search?query=Health+Insurance+%28General+Medical+Service+Table%29+Regulations+2021\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- requirements below must be met in addition to common principles for time tiered health assessment\nitems, contained in AN.0.36.\nUSE OF ITEMS\nThe specific requirements of the Type 2 Diabetes Risk Evaluation are set out in clause 2.15.5 of the Health\nInsurance (General Medical Service Table) Regulations 2021 (the Regulations).\n76\n\n[page 77]\nThe Regulations specify GPs (see GN.4.13) and prescribed medical practitioners (PMP, see AN.7.1) can provide\nthis health assessment to patients, where in the clinical judgement of the attending medical practitioner, a specific\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- addition to common principles for time-tiered health assessment\nitems, contained in AN.0.36.\nUSE OF THE ITEMS\nThe specific requirements of the Comprehensive Medical Assessment for care recipients in a RACF are set out in\nclause 2.15.7 of the Health Insurance (General Medical Service Table) Regulations 2021 (the Regulations).\nThe regulations require that a Comprehensive Medical Assessment for care a recipient in a RACF must include an\nassessment of the resident's health, physical and psychological function.\nIt must also include:\n• a personal attendance by a gene\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Health Insurance Regulations 2018\n\n**Type**: Regulation\n**Confidence**: medium\n**Mentions**: 2\n**Register search**: https://www.legislation.gov.au/search?query=Health+Insurance+Regulations+2018\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- ries of medical practitioners able to use the MBS GP\nitems can be found on the Federal Register of Legislation, and are set out in three regulatory instruments:\n• Health Insurance Act 1973\n• Health Insurance (General Medical Services Table) Regulations 2021\n• Health Insurance Regulations 2018\nGN.5.14 Recognition as a Specialist or Consultant Physician\nA medical practitioner who:\n· is registered as a specialist under State or Territory law; or\n· holds a fellowship of a specified specialist College and has obtained, after successfully completing an\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- ferred rate, a duplicate or replacement\nletter of referral must be obtained by the specialist or the consultant physician.\nEmergency situations\nMedicare benefits are payable even though there is no written referral in an emergency situation (as defined in the\nHealth Insurance Regulations 2018). The specialist or the consultant physician should be of the opinion that the\nservice must be rendered as quickly as possible and endorses the account, receipt or assignment form as an\n\"Emergency referral\".\nA referral must be obtained from a medical practiti\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Under the Health Insurance Act 1973\n\n**Type**: Act\n**Confidence**: medium\n**Mentions**: 2\n**Register search**: https://www.legislation.gov.au/search?query=Under+the+Health+Insurance+Act+1973\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- sts and Medicare benefits are\npayable at referred rates.\nGN.7.17 Billing procedures\nThe Services Australia website contains information on Medicare billing and claiming options. Please visit the\nServices Australia website for further information.\nBulk billing\nUnder the Health Insurance Act 1973, a bulk billing facility for professional services is available to all persons in\nAustralia who are eligible for a benefit under the Medicare program. If a practitioner bulk bills for a service the\npractitioner undertakes to accept the relevant Medicare benef\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n- . Duplicates of\naccounts or receipts should be clearly marked \"duplicate\" and should be issued only where the original has been lost.\nDuplicates should not be issued as a routine system for \"accounts rendered\".\nAssignment of benefit (bulk billed) arrangements\nUnder the Health Insurance Act 1973 an Assignment of Benefit (bulk-billing) facility for professional services is\navailable to all persons in Australia who are eligible for benefit under the Medicare program. This facility is NOT\nconfined to pensioners or people in special need.\nIf an optometri\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Health Insurance Regulation 2018\n\n**Type**: Regulation\n**Confidence**: medium\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Health+Insurance+Regulation+2018\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- placement organisation must advise Services Australia of the placement before MBS GP items can be\naccessed.\n3. Medical practitioners on the Vocational Register of GPs\nThe Vocational Register of GPs closed to new participants on 16 June 2021.\nSection 16 of the Health Insurance Regulation 2018 allows medical practitioners whose names are entered onto the\nVocational Register of GPs to access MBS GP items provided they continue to be registered with Ahpra.\n4. Eligible non-vocationally recognised medical practitioners\nThe programs below closed to new\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Private Health Insurance (Benefit Requirement) Rules 2011\n\n**Type**: Rules\n**Confidence**: medium\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Private+Health+Insurance+%28Benefit+Requirement%29+Rules+2011\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- fore do not attract a rebate of 75% of the Schedule fee unless certified\nas a 'Type C' treatment. A list of most MBS items in scope of this exception, and the requirements around certifying\na treatment as 'Type C' can be found in the Private Health Insurance (Benefit Requirement) Rules 2011. Services\nprovided to a private patient in an emergency department are exempted under the Private Health Insurance (Health\nInsurance Business) Rules 2018.\nMedicare benefits are claimable only for 'clinically relevant' services rendered by an appropriate healt\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Private Health Insurance (Health Insurance Business) Rules 2018\n\n**Type**: Rules\n**Confidence**: medium\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Private+Health+Insurance+%28Health+Insurance+Business%29+Rules+2018\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- n, and the requirements around certifying\na treatment as 'Type C' can be found in the Private Health Insurance (Benefit Requirement) Rules 2011. Services\nprovided to a private patient in an emergency department are exempted under the Private Health Insurance (Health\nInsurance Business) Rules 2018.\nMedicare benefits are claimable only for 'clinically relevant' services rendered by an appropriate health practitioner.\nA 'clinically relevant' service is one which is generally accepted by the relevant profession as necessary for the\nappropriate treatment o\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Telehealth and Telephone Attendances) Determination 2021\n\n**Type**: Determination\n**Confidence**: medium\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Telehealth+and+Telephone+Attendances%29+Determination+2021\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- instruments:\n• Health Insurance (Section 3C General Medical Service – Other Medical Practitioner) Determination 2018\n– items 733, 737, 741, 745, 761, 763, 766, 769, 772, 776, 788, 789, 2197, 2198, 2200\n• Health Insurance (Section 3C General Medical Services – Telehealth and Telephone Attendances)\nDetermination 2021 – telehealth (video) and telephone attendance items.\n44\n\n[page 45]\n• Health Insurance (General Medical Services Table) Regulations 2021 – all other attendance items.\nAN.0.11 Derived fee items for general practice\nDerived fees apply to a range of attendance it\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Public Governance, Performance and Accountability Act 2013\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 2\n**Register search**: https://www.legislation.gov.au/search?query=Public+Governance%2C+Performance+and+Accountability+Act+2013\n\n**Sources**:\n- `pages/about.html`\n- `pages/homepage.html`\n\n**Evidence contexts**:\n- breadth of Australia’s health system and include experts and officials from government, clinical practice and other key sectors.\nAudit and Risk Committee\nThe Audit and Risk Committee (ARC) has been established by the Board in compliance with section 45 of the\nPublic Governance, Performance and Accountability Act 2013 (PGPA Act)\nand the\nPublic Governance, Performance and Accountability Rule (PGPA Rule)\nsection 17: Audit Committees for Commonwealth Entities.\nThe Committee assists the Board discharge its responsibilities under the\nNational Health Reform Act 2011\nand the PGPA\n  Source: `pages/about.html`\n- breadth of Australia’s health system and include experts and officials from government, clinical practice and other key sectors.\nAudit and Risk Committee\nThe Audit and Risk Committee (ARC) has been established by the Board in compliance with section 45 of the\nPublic Governance, Performance and Accountability Act 2013 (PGPA Act)\nand the\nPublic Governance, Performance and Accountability Rule (PGPA Rule)\nsection 17: Audit Committees for Commonwealth Entities.\nThe Committee assists the Board discharge its responsibilities under the\nNational Health Reform Act 2011\nand the PGPA\n  Source: `pages/homepage.html`\n\n### Approval Scheme Therapeutic Goods Act 1989\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Approval+Scheme+Therapeutic+Goods+Act+1989\n\n**Sources**:\n- `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pages.jsonl`\n\n**Evidence contexts**:\n- and is administered by the TGA. Under the\nCTN scheme, therapeutic goods are permitted to be used for experimental\npurposes if the relevant clinical trial is notified to the TGA.\nClinical Trial The Clinical Trial Approval (CTA) Scheme is established under the\nApproval Scheme Therapeutic Goods Act 1989 (Cth) and is administered by the TGA. Under the\nCTA scheme, therapeutic goods are permitted to be used for experimental\npurposes if the relevant clinical trial is approved by the TGA.\nClinical trial team The clinical trial team includes individuals, identifie\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pages.jsonl`\n\n### Notification Scheme Therapeutic Goods Act 1989\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Notification+Scheme+Therapeutic+Goods+Act+1989\n\n**Sources**:\n- `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pages.jsonl`\n\n**Evidence contexts**:\n- perimental drugs\n■ Biological products\n■ Medical devices\n■ Health-related service changes\n■ Health-related preventative strategies\n■ Health-related educational interventions.\nClinical Trial The Clinical Trial Notification Scheme (CTN) is established under the\nNotification Scheme Therapeutic Goods Act 1989 (Cth) and is administered by the TGA. Under the\nCTN scheme, therapeutic goods are permitted to be used for experimental\npurposes if the relevant clinical trial is notified to the TGA.\nClinical Trial The Clinical Trial Approval (CTA) Scheme is established unde\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pages.jsonl`\n\n### Other Medical Practitioner) Determination 2018\n\n**Type**: Determination\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Other+Medical+Practitioner%29+Determination+2018\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- Details about the legislative requirements of the MBS item(s) can be found on the Federal Register of Legislation at\nwww.legislation.gov.au. Attendance items are set out in three regulatory instruments:\n• Health Insurance (Section 3C General Medical Service – Other Medical Practitioner) Determination 2018\n– items 733, 737, 741, 745, 761, 763, 766, 769, 772, 776, 788, 789, 2197, 2198, 2200\n• Health Insurance (Section 3C General Medical Services – Telehealth and Telephone Attendances)\nDetermination 2021 – telehealth (video) and telephone attendance items.\n44\n\n[p\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Therapeutic Goods Act 1989\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Therapeutic+Goods+Act+1989\n\n**Sources**:\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n**Evidence contexts**:\n- dered according to the provisions of the relevant Commonwealth, State and\nTerritory laws. For example, medical practitioners must ensure that the medicines and medical devices they use have\nbeen supplied to them in strict accordance with the provisions of the Therapeutic Goods Act 1989.\nWhere a Medicare benefit has been inappropriately paid, Services Australia may request its return from the\npractitioner concerned.\n* MBS items 10988 and 10989 generally attract a 100% rebate but can be specified as 'Type C' treatments and\nattract a 75% rebat\n  Source: `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl`\n\n### Therapeutic Goods Regulations 1990\n\n**Type**: Regulation\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Therapeutic+Goods+Regulations+1990\n\n**Sources**:\n- `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pages.jsonl`\n\n**Evidence contexts**:\n- a review of the role\nreferences to the legislation). Therapeutic\nof consumer representatives in health\nGoods Regulations 1990 Therapeutic\ndecision-making. Canberra: CHF; 2015.\nGoods Regulations 1990 Fee provisions in\n65. Cancer Australia. Organisational self-\nTherapeutic Goods Regulations 1990.\nassessment survey for consumer\n54. Policy on Good Clinical Practice Training for\nengagement. Sydney: Cancer Australia;\nNational Institutes of Health (NIH) Awardees\n2013.\nInvolved in NIH-funded Clinical Trials NOT-\n66. Australian Council on Healthcare Standar\n  Source: `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pages.jsonl`\n\n## Files Scanned\n\n- `pages/about.html` (page)\n- `pages/homepage.html` (page)\n- `pages/news-latest.html` (page)\n- `pages/strategies-index.html` (page)\n- `pages/strategies-index__00.html` (page)\n- `pages/strategies-index__01.html` (page)\n- `pages/strategies-index__02.html` (page)\n- `pages/strategies-index__03.html` (page)\n- `pages/strategies-index__04.html` (page)\n- `pages/strategies-index__05.html` (page)\n- `pages/strategies-index__06.html` (page)\n- `pages/strategies-index__07.html` (page)\n- `pages/strategies-index__08.html` (page)\n- `pages/strategies-index__09.html` (page)\n- `pages/strategies-index__10.html` (page)\n- `pages/strategies-index__11.html` (page)\n- `pages/strategies-index__12.html` (page)\n- `pages/strategies-index__13.html` (page)\n- `pages/strategies-index__14.html` (page)\n- `pages/strategies-index__15.html` (page)\n- `pages/strategies-index__16.html` (page)\n- `pages/strategies-index__17.html` (page)\n- `pages/strategies-index__18.html` (page)\n- `pages/strategies-index__19.html` (page)\n- `pages/structure.html` (page)\n- `other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pages.jsonl` (pdf_pages)\n- `other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pages.jsonl` (pdf_pages)\n- `strategies/Manchester-Patient-Safety-Framework.pages.jsonl` (pdf_pages)",
  "global_initiatives_md": null,
  "strategy": {
    "reporting_period": "2024-25",
    "corporate_plan_period": "2025-26",
    "vision": null,
    "vision_source_page": null,
    "purposes": null,
    "purposes_source_page": null,
    "how_we_deliver": null,
    "how_we_deliver_source_page": null,
    "government_priorities": [],
    "outcomes": [],
    "values": [],
    "values_framework_name": null,
    "kpi_targets_2025_26": [],
    "kpi_results_2024_25": [],
    "_source_urls": {
      "annual_report_url": "",
      "corporate_plan_url": ""
    }
  },
  "ideas": [
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Risk & Assurance",
      "scale": "small",
      "title": "Recommendation tracker for audits, reviews, and inquiries",
      "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.",
      "quote": "Audit and Risk Committee\nThe Audit and Risk Committee (ARC) has been established by the Board in compliance with section 45 of the\nPublic Governance, Performance and Accountability Act 2013 (PGPA Act)\nand the\nPublic Governance, Performance and Accountability Rule (PGPA Rule)\nsection 17: Audit Committees for Commonwealth Entities.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "pages/about.html (https://www.safetyandquality.gov.au/about-us/committees)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Risk & Assurance",
      "scale": "large",
      "title": "Integrated assurance and lessons-learned system",
      "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.",
      "quote": "Audit and Risk Committee\nThe Audit and Risk Committee (ARC) has been established by the Board in compliance with section 45 of the\nPublic Governance, Performance and Accountability Act 2013 (PGPA Act)\nand the\nPublic Governance, Performance and Accountability Rule (PGPA Rule)\nsection 17: Audit Committees for Commonwealth Entities.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "pages/about.html (https://www.safetyandquality.gov.au/about-us/committees)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Case Processing",
      "scale": "small",
      "title": "Triage queue for stuck or ageing cases",
      "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.",
      "quote": "Details of the requirements for a\nhealth assessment for each patient cohort are at:\n• Type 2 diabetes risk evaluation (40-49 years) – see AN.0.37.\n• Health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease –\nsee AN.0.38.\n• Health Assessment provided for people aged 75 years and older – see AN.0.39.\n• Health Assessment provided as a comprehensive medical assessment for residents of residential aged care\nfacilities – see AN.0.40.\n• Health Assessment provided for people with an intellectual disability – see AN.0.41.\n• Health Assessment provided for refugees and other humanitarian entrants – see AN.0.42.\n• One-off health assessment for veterans – see AN.0.69.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Case Processing",
      "scale": "large",
      "title": "End-to-end case processing redesign",
      "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.",
      "quote": "Details of the requirements for a\nhealth assessment for each patient cohort are at:\n• Type 2 diabetes risk evaluation (40-49 years) – see AN.0.37.\n• Health assessment for people aged 45-49 years (inclusive) who are at risk of developing chronic disease –\nsee AN.0.38.\n• Health Assessment provided for people aged 75 years and older – see AN.0.39.\n• Health Assessment provided as a comprehensive medical assessment for residents of residential aged care\nfacilities – see AN.0.40.\n• Health Assessment provided for people with an intellectual disability – see AN.0.41.\n• Health Assessment provided for refugees and other humanitarian entrants – see AN.0.42.\n• One-off health assessment for veterans – see AN.0.69.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf (https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Citizen Services",
      "scale": "small",
      "title": "Plain-language service pages and proactive status updates",
      "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.",
      "quote": "[pages 46,47,48]\nrocedures and protocols that define a vision, principles, objectives, practices, roles and\nfunctions, resources, service outcomes and how outcomes will be measured\n■ Ensure that enough resources are allocated to the health service organisation’s risk\nmanagement system\n■ Foster an organisational culture that focuses on quality clinical trial service provision and\ncontinuous improvement in identifying and managing risk\n■ Incorporate systematic audits of safety and quality systems relating to clinical trial service provision\nin the whole-of-organisation audit program\n■ Ensure availability of data and information to support quality assurance and review of clinical trial\nservices across the health service organisation or trial site\n42 | Australian Commission on Safety and Quality in Health Care",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / service users",
      "source": "other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Citizen Services",
      "scale": "large",
      "title": "Single front door for life-event based services",
      "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.",
      "quote": "[pages 46,47,48]\nrocedures and protocols that define a vision, principles, objectives, practices, roles and\nfunctions, resources, service outcomes and how outcomes will be measured\n■ Ensure that enough resources are allocated to the health service organisation’s risk\nmanagement system\n■ Foster an organisational culture that focuses on quality clinical trial service provision and\ncontinuous improvement in identifying and managing risk\n■ Incorporate systematic audits of safety and quality systems relating to clinical trial service provision\nin the whole-of-organisation audit program\n■ Ensure availability of data and information to support quality assurance and review of clinical trial\nservices across the health service organisation or trial site\n42 | Australian Commission on Safety and Quality in Health Care",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / service users",
      "source": "other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Data & Performance",
      "scale": "small",
      "title": "KPI evidence register with named owners",
      "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.",
      "quote": "[Page 43]\nExamples of evidence\n■ Policy documents that describe the process for monitoring the quality of clinical trial\nservice provision\n■ Feedback from the workforce about the use of clinical trial operational performance data\n■ Feedback from consumers about their involvement in the review of safety and quality\nperformance data\n■ Quality improvement plan that includes actions to deal with identified risks and issues as they arise\n■ Examples of specific improvement activities that have been implemented and evaluated\n■ Committee and meeting records in which reports, presentations, and performance data are\nregularly reviewed and reported to the governing body or relevant committees\n■ Audit report from regulatory agencies and trial sponsor organisations, presentations and analysis\nof quality performance data\n■ Documented national quality performance measures such as:",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Data & Performance",
      "scale": "large",
      "title": "Outcome dashboard linking budget, delivery, and public impact",
      "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.",
      "quote": "[Page 43]\nExamples of evidence\n■ Policy documents that describe the process for monitoring the quality of clinical trial\nservice provision\n■ Feedback from the workforce about the use of clinical trial operational performance data\n■ Feedback from consumers about their involvement in the review of safety and quality\nperformance data\n■ Quality improvement plan that includes actions to deal with identified risks and issues as they arise\n■ Examples of specific improvement activities that have been implemented and evaluated\n■ Committee and meeting records in which reports, presentations, and performance data are\nregularly reviewed and reported to the governing body or relevant committees\n■ Audit report from regulatory agencies and trial sponsor organisations, presentations and analysis\nof quality performance data\n■ Documented national quality performance measures such as:",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Regulation & Policy",
      "scale": "small",
      "title": "Regulatory burden scan for forms, guidance, and reporting",
      "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.",
      "quote": "WA\nAdditional key stakeholders\nIndividuals who participated in the development and pilot of the Governance Framework, who will also have a key role in implementing the Governance Framework in their organisations, accompanied Dr Murphy in the launch:\nProfessor Erwin Loh, Group Chief Medical Officer, St Vincent's Health Australia\nMs Nicole Rasmussen, Director, Patient Safety and Improvement, Alfred Health\nA/Professor Lewis Campbell, Staff Specialist Intensive Care Unit, Royal Darwin Hospital\nMs Sue Brew, Clinical Trial Coordinator, Canberra Hospital\nMs Anne McKenzie AM, Consumer Advocate\nNational launch of the Governance Framework\nThe Governance Framework was launched by Dr Brendan Murphy, Secretary of the Australian Government Department of Health, on 24 May 2022 at the annual ARCS Conference.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/strategies-index__15.html (https://www.safetyandquality.gov.au/national-standards/clinical-trials-governance-framework/about-national-clinical-trials-governance-framework)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Regulation & Policy",
      "scale": "large",
      "title": "Adaptive regulation program with live feedback loops",
      "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.",
      "quote": "WA\nAdditional key stakeholders\nIndividuals who participated in the development and pilot of the Governance Framework, who will also have a key role in implementing the Governance Framework in their organisations, accompanied Dr Murphy in the launch:\nProfessor Erwin Loh, Group Chief Medical Officer, St Vincent's Health Australia\nMs Nicole Rasmussen, Director, Patient Safety and Improvement, Alfred Health\nA/Professor Lewis Campbell, Staff Specialist Intensive Care Unit, Royal Darwin Hospital\nMs Sue Brew, Clinical Trial Coordinator, Canberra Hospital\nMs Anne McKenzie AM, Consumer Advocate\nNational launch of the Governance Framework\nThe Governance Framework was launched by Dr Brendan Murphy, Secretary of the Australian Government Department of Health, on 24 May 2022 at the annual ARCS Conference.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/strategies-index__15.html (https://www.safetyandquality.gov.au/national-standards/clinical-trials-governance-framework/about-national-clinical-trials-governance-framework)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Citizen Participation",
      "scale": "small",
      "title": "Consultation feedback summaries with response tracking",
      "idea": "Summarise consultation submissions by theme and publish what changed in response.",
      "quote": "[pages 12,13,14]\nrganisation is being governance systems.\nproperly managed, including that\n− systems of production or service delivery\nare well designed and fit for purpose\n− services meet desired standards\n− the organisation meets its compliance\nobligations\n■ Challenges the assumptions of management\n■ Reviews and monitoring performance of the\ncontrol framework to ensure that major risks\nare identified and managed\n■ Ensures that there is an ongoing focus on\nquality improvement\n■ Evaluates reports, and reviewing feedback,\nsuggestions and complaints\n■ Ensures the continuing development of the\nexecutive management team\n■ Plans for succession\n■ Communicates with, and is accountable to,\npatients and consumers and, internal and\nexternal stakeholders.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "category": "Citizen Participation",
      "scale": "large",
      "title": "Always-on policy participation platform",
      "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.",
      "quote": "[pages 12,13,14]\nrganisation is being governance systems.\nproperly managed, including that\n− systems of production or service delivery\nare well designed and fit for purpose\n− services meet desired standards\n− the organisation meets its compliance\nobligations\n■ Challenges the assumptions of management\n■ Reviews and monitoring performance of the\ncontrol framework to ensure that major risks\nare identified and managed\n■ Ensures that there is an ongoing focus on\nquality improvement\n■ Evaluates reports, and reviewing feedback,\nsuggestions and complaints\n■ Ensures the continuing development of the\nexecutive management team\n■ Plans for succession\n■ Communicates with, and is accountable to,\npatients and consumers and, internal and\nexternal stakeholders.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf (https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    }
  ],
  "legislation_administered": [],
  "artifacts": [
    {
      "category": "strategies",
      "year": "2012",
      "url": "https://www.ajustnhs.com/wp-content/uploads/2012/10/Manchester-Patient-Safety-Framework.pdf",
      "file": "strategies/Manchester-Patient-Safety-Framework.pdf",
      "bytes": 144955,
      "link_text": "MaPSaF"
    },
    {
      "category": "other-pdfs",
      "year": "2020",
      "url": "https://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/B013E0789A07D708CA258B030013670A/$File/PDF%20Version%20-%201%20July%202024%20Category%201%20-%20Professional%20Attendances.pdf",
      "file": "other-pdfs/PDF-20Version-20--201-20July-202024-20Category-201-20--20Professional-20Attendan.pdf",
      "bytes": 3077636,
      "link_text": "Medicare Benefits Schedule Book, Category 1"
    },
    {
      "category": "other-pdfs",
      "year": "2022",
      "url": "https://www.safetyandquality.gov.au/sites/default/files/resources/attachments//final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30_may_2022.pdf",
      "file": "other-pdfs/final_design_-_national_clinical_trials_governance_framework_and_user_guide_-_30.pdf",
      "bytes": 1176425,
      "link_text": "Download PDF - 1.12 MB"
    }
  ],
  "_meta": {
    "snapshot_built_at": "2026-05-13T11:02:37+00:00",
    "strategy_brief_meta": {
      "model": "nova-micro",
      "folder": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "annual_report": {
        "file": null,
        "url": "",
        "year": null
      },
      "corporate_plan": {
        "file": "strategies\\Manchester-Patient-Safety-Framework.txt",
        "url": "https://www.ajustnhs.com/wp-content/uploads/2012/10/Manchester-Patient-Safety-Framework.pdf",
        "year": null
      },
      "usage": {
        "input_tokens": 7528,
        "output_tokens": 155,
        "total_tokens": 7683,
        "model": "nova-micro"
      },
      "cost_usd": 0.00028518,
      "elapsed_seconds": 1.16,
      "generated_at": "2026-05-13T05:15:35+00:00"
    },
    "ideas_manifest": {
      "entity_id": "B-002552",
      "entity_name": "Australian Commission on Safety and Quality in Health Care's Primary Care Commit",
      "folder_name": "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit",
      "generated_at": "2026-05-09T23:05:39.211663+00:00",
      "idea_count": 12,
      "markdown": "ideas/Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit_ideas.md",
      "jsonl": "ideas/ideas.jsonl",
      "inputs": [
        "Australian-Commission-on-Safety-and-Quality-in-Health-Care-s-Primary-Care-Commit_strategy-overview.md",
        "strategy-evidence.json",
        "global-intelligence/source-manifest.json"
      ]
    },
    "global_intel_meta": null
  }
}